Essex Property Trust: The Best Time To Buy Apartment REITs Since 2008
Essex Property Trust (NYSE:ESS) is an apartment REIT focused on the West Coast markets. ESS stock has traditionally traded at nosebleed valuations due its seemingly unstoppable business model, but the stock has slid amidst the rising interest rate environment. The stock price weakness may also be…#essexpropertytrust #westcoast #ess #seattle #bbb #ffo #google (Source: Reuters: Health)
Source: Reuters: Health - April 12, 2023 Category: Consumer Health News Source Type: news
Three die from mystery nosebleed-causing disease in Burundi
Cases have all been logged in north eastern Burundi in the commune of Gitobe in the Kirundo province and the Butihinda commune, in the province of Muyinga. (Source: the Mail online | Health)
Source: the Mail online | Health - March 29, 2023 Category: Consumer Health News Source Type: news
Baltimore startup raising $4M to make nosebleeds easier to manage
Dr. Elizabeth Clayborne used to make do-it-yourself nose clips out of tongue depressors to stop patients' nosebleeds from flowing onto the floor.
The University of Maryland emergency room physician is hunting for $4 million in seed funding to bring a device that replaces the tongue depressors — NasaClip — to a wider market. Patients can treat their nosebleeds at home using the device instead of rushing to a hospital and it gives doctors a tool more advanced than a few sticks and some tape. Nosebleeds… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 10, 2023 Category: American Health Authors: Matt Hooke Source Type: news
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Angel investing in Black startups plummeted after 2020. These investors are trying to reverse the trend
As a young physician, Dr. Elizabeth Clayborne saw a need for a better way to stop nosebleeds, a common condition she saw at the hospital where she worked, especially among children. She developed a bandage-like device for your nose and secured patents for her invention, called “NasaClip.” Then, in…#elizabethclayborne #nasaclip #georgefloyd #patgouhin #jilljohnson #newark #newjersey #ifel #makingofblackangels #ginanisbeth (Source: Reuters: Health)
Source: Reuters: Health - February 24, 2023 Category: Consumer Health News Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
What can I do to stop my regular nosebleeds? DR MARTIN SCURR answers your health questions
DR MARTIN SCURR: Nosebleeds fall into two categories - anterior and posterior - depending on which blood vessel the bleeding stems from. (Source: the Mail online | Health)
Source: the Mail online | Health - December 6, 2022 Category: Consumer Health News Source Type: news
Painkiller warning: Nosebleeds could signal ‘life-threatening' side effect - 'Call GP now'
WITH most medicine there is the risk of side effects. However, some can cause more serious issues than others. And if you experience any more extreme effects, it is likely you should seek medical help. (Source: Daily Express - Health)
Source: Daily Express - Health - July 20, 2022 Category: Consumer Health News Source Type: news
Tanzania: Govt Moves to Contain Nosebleed Disease
[Daily News] PRELIMINARY specimens taken from patients suffering nosebleed disease in Lindi Region have tested negative for Ebola, Marburg and Covid-19, as the government intensifies measures to contain the contagion, Chief Medical Officer Dr AifelloSichalwe confirmed. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 14, 2022 Category: African Health Source Type: news
Tanzania: Strange Nosebleed Disease Kills Three in Lindi
[Daily News] Three out of 13 patients are confirmed dead of a strange nosebleed disease in Lindi. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 13, 2022 Category: African Health Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Mayo Clinic Q and A: Managing nosebleeds
DEAR MAYO CLINIC: My daughter seems to be prone to nosebleeds, and I am unsure why. She is 19 and has allergies. Over the past few months, she has experienced several nosebleeds that lasted a long time. She has had no trauma to her nose. Why does this happen, and how can I help her? ANSWER: At some point, almost everyone will experience a nosebleed, also known as epistaxis. They are fairly common, especially during dry winter… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 12, 2022 Category: Databases & Libraries Source Type: news
Statins: Side effects of atorvastatin may include nosebleeds - other symptoms
STATINS are an effective group of medicines used to combat high cholesterol. Like other medicines they can cause side effects, some more dramatic than others. (Source: Daily Express - Health)
Source: Daily Express - Health - April 25, 2022 Category: Consumer Health News Source Type: news
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
